Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation
Piccini J, Ahlsson A, Dorian P, Gillinov A, Kowey P, Mack M, Milano C, Noiseux N, Perrault L, Ryan W, Steinberg J, Voisine P, Waldron N, Gleason K, Titanji W, Leaback R, O’Sullivan A, Ferguson W, Benussi S, Investigators N, Akhter S, Andreas M, Benussi S, Castella M, Dalrymple-Hay M, El-Eshmawi A, Groh M, Hanke T, Jeanmart H, Katz M, McCullough J, Melby S, Miller J, Noiseux N, Romano M, Perrault L, Piccini J, Podgoreanu M, Ryan W, Sharma V, Shults C, Teman N, Voisine P, Whitson B, Wickbom A, Vallabhajosyula P, Yau T. Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation. JACC Clinical Electrophysiology 2024, 10: 930-940. PMID: 38661602, DOI: 10.1016/j.jacep.2024.01.020.Peer-Reviewed Original ResearchPrevention of postoperative atrial fibrillationPostoperative atrial fibrillationCoronary artery bypass graftingRate of postoperative atrial fibrillationSafety of botulinum toxin type ACardiac surgeryPrimary endpointBotulinum toxin type AToxin type AAtrial fibrillationAssociated with increased morbidityRate of adverse eventsDose-ranging studyPlacebo-controlled trialOpen-chest cardiac surgeryType of surgeryEpicardial fat padsInjection of botulinum toxinArtery bypass graftingRandomized clinical trialsPlacebo-ControlledValve surgeryDouble-blindPlacebo groupContinuous AF
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply